FDA approves Protein Sciences quadrivalent flu vaccine

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Baluchis
Image: iStock/Baluchis

Related tags: Influenza, Vaccine, Influenza vaccine

The US FDA has approved a quadrivalent formulation of Protein Sciences’ vaccine, Flublok, produced without eggs or the influenza virus.

According to the vaccine maker, Flublok Quadrivalent is the first high antigen content quadrivalent flu to be approved by the US Food and Drug Administration (FDA).

“The US has been trending toward the use of quadrivalent flu vaccines in recent years,”​ said Manon Cox, CEO of Protein Sciences Corporation. “We are looking forward to launching the vaccine next year and, in the meantime, continuing to make trivalent Flublok available this year.”

The vaccine protects against four strains of influenza: three of the same strains found in trivalent Flublok plus an additional B strain, and like the trivalent product is not reliant on traditional manufacturing processes.

Rather than use production methods that involve growing live influenza virus in hens eggs, Protein Sciences employs an insect virus-based expression system to make large quantities of viral hemagglutinin, the protein that elicits the strongest immune response

Such an approach removes the risk of contamination from the live virus or hens egg and offers significant time advantages, the firm previously told this publication​.

We can manufacture vaccine in significantly less time  - 2-3 months vs. 6 months - and that can be shortened even further to a few weeks if we already have recombinant baculoviruses made/stored that express the desired hemagglutinin protein​,”spokeswoman Rachael Felberbaum said.

Protein Sciences’ manufacturing plant is the Pearl River facility​ in New York, refitted in just ten weeks after the firm acquired the site from Pfizer in 2012.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more